Insmed (INSM) Total Current Liabilities (2010 - 2026)
Insmed's (INSM) quarterly Total Current Liabilities came in at $361.0 million in Q1 2026, up 50.9% year-on-year from $239.2 million in Q1 2025, and down 23.01% quarter-over-quarter from $468.9 million in Q4 2025.
Insmed (INSM) Total Current Liabilities (2010 - 2026) Analysis & Trends
Insmed's Total Current Liabilities history runs 17 years deep, the most recent figure standing at $361.0 million for Q1 2026.
- On a quarterly basis, Total Current Liabilities rose 50.9% year-over-year to $361.0 million in Q1 2026; TTM through Mar 2026 was $361.0 million, a 50.9% increase from a year earlier, with the FY2025 full-year figure at $468.9 million, up 57.59% from the prior year.
- Total Current Liabilities slipped to $361.0 million in Q1 2026 per INSM's latest filing, from $468.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $524.2 million in Q2 2024 and bottomed at $113.8 million in Q2 2022.
- The 5-year median for Total Current Liabilities is $239.2 million (2025), against an average of $275.4 million.
- Across the five-year window, Total Current Liabilities soared 156.61% in 2024 and tumbled 43.16% in 2025, its largest moves.
- Year by year, Total Current Liabilities stood at $190.2 million in 2022, then climbed by 18.6% to $225.6 million in 2023, then jumped by 31.87% to $297.5 million in 2024, then soared by 57.59% to $468.9 million in 2025, then slipped by 23.01% to $361.0 million in 2026.
- Per Business Quant, the three latest INSM Total Current Liabilities figures stand at $361.0 million (Q1 2026), $468.9 million (Q4 2025), and $417.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Insmed | 23.26 Bn | 22.03 Bn | 258.54 Mn | 361.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 361.01 Mn |
| Dec 31, 2025 | 468.87 Mn |
| Sep 30, 2025 | 417.21 Mn |
| Jun 30, 2025 | 311.68 Mn |
| Mar 31, 2025 | 239.23 Mn |
| Dec 31, 2024 | 297.53 Mn |
| Sep 30, 2024 | 259.19 Mn |
| Jun 30, 2024 | 524.15 Mn |
| Mar 31, 2024 | 420.86 Mn |
| Dec 31, 2023 | 225.63 Mn |
| Sep 30, 2023 | 196.73 Mn |
| Jun 30, 2023 | 204.26 Mn |
| Mar 31, 2023 | 187.98 Mn |
| Dec 31, 2022 | 190.24 Mn |
| Sep 30, 2022 | 137.65 Mn |
| Jun 30, 2022 | 113.82 Mn |
| Mar 31, 2022 | 125.25 Mn |
| Dec 31, 2021 | 135.17 Mn |
| Sep 30, 2021 | 112.50 Mn |
| Jun 30, 2021 | 99.66 Mn |